Oxford Nanopore
Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments â MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.
Oxford Nanopore Facts
CEO: Gordon Sanghera
Website: www.nanoporetech.com
Ticker symbol: Privately held
Headquarters: Oxford, UK
Number of employees: 250+
JPM Healthcare Conference Day 2: Thermo Fisher, BD, SomaLogic, Myriad, Oxford Nanopore, More
Highlights of the second day included Myriad Genetics' new oncology testing service and more details on SomaLogic's partnership with Illumina.
Akoya, Olink, NanoString, Adaptive Bio, Sema4, Oxford Nanopore Report Preliminary Financial Results
The life science tools companies provided anticipated revenue results for the fourth quarter and full-year 2021.
The firm raised its 2023 revenue guidance to between £170 million and £190 million and said it expects revenue between £135 million and £145 million in 2022.
Published in Science, the work enables more controlled translocation of peptides through nanopores and allows for repeated reads of individual peptides.
JP Morgan Initiates Coverage of Oxford Nanopore Technologies With Overweight Rating
Oxford Nanopore is a "differentiated player, operating in an attractive segment, with a very strong long-term top-line growth outlook," according to a JP Morgan analyst.